In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sarepta options Duke's CRISPR/Cas9 IP for DMD

Executive Summary

Sarepta Therapeutics Inc. is working with Duke University to develop a treatment for Duchenne muscular dystrophy (DMD) and gains an option to exclusively license the university’s CRISPR/Cas9 gene editing technology in this indication. DMD is a rare muscle-wasting disease caused by a mutation in the dystrophin gene (an essential protein involved in muscular function).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies